Long Non-Coding RNAs as Determinants of Thyroid Cancer Phenotypes: Investigating Differential Gene Expression Patterns and Novel Biomarker Discovery

• Published in: Biology (Basel, Switzerland) Switzerland), 2024-05, Vol.13 (5), p.304
• Main Authors: DeSouza, Nicole R, Jarboe, Tara, Carnazza, Michelle, Quaranto, Danielle, Islam, Humayun K, Tiwari, Raj K, Geliebter, Jan
• Format: Article
• Language: English
• Subjects: anaplastic thyroid cancer; Biomarkers; Cancer; Carcinogens; Development and progression; Gene expression; Genes; Genetic aspects; Genomics; Health aspects; Homeopathy; Identification; Investigations; Kinases; lncRNA; Malignancy; Materia medica and therapeutics; Medical prognosis; Metastasis; MicroRNAs; miRNA; Mortality; Mutation; Non-coding RNA; Papillary thyroid cancer; Phenotypes; Physiology; Proteins; RNA; Signal transduction; Therapeutic targets; Therapeutics; Thyroid cancer; Tumors
• ISSN: 2079-7737; 2079-7737
• DOI: 10.3390/biology13050304

Thyroid Cancer (TC) is the most common endocrine malignancy, with increasing incidence globally. Papillary thyroid cancer (PTC), a differentiated form of TC, accounts for approximately 90% of TC and occurs predominantly in women of childbearing age. Although responsive to current treatments, recurrence of PTC by middle age is common and is much more refractive to treatment. Undifferentiated TC, particularly anaplastic thyroid cancer (ATC), is the most aggressive TC subtype, characterized by it being resistant and unresponsive to all therapeutic and surgical interventions. Further, ATC is one of the most aggressive and lethal malignancies across all cancer types. Despite the differences in therapeutic needs in differentiated vs. undifferentiated TC subtypes, there is a critical unmet need for the identification of molecular biomarkers that can aid in early diagnosis, prognosis, and actionable therapeutic targets for intervention. Advances in the field of cancer genomics have enabled for the elucidation of differential gene expression patterns between tumors and healthy tissue. A novel category of molecules, known as non-coding RNAs, can themselves be differentially expressed, and extensively contribute to the up- and downregulation of protein coding genes, serving as master orchestrators of regulated and dysregulated gene expression patterns. These non-coding RNAs have been identified for their roles in driving carcinogenic patterns at various stages of tumor development and have become attractive targets for study. The identification of specific genes that are differentially expressed can give insight into mechanisms that drive carcinogenic patterns, filling the gaps of deciphering molecular and cellular processes that modulate TC subtypes, outside of well-known driver mutations.